Tue, Apr 05
|Virtual/Live
Kicking Cancer's KRAS Expert Series with Dr. Shokat
Kevan M. Shokat, Ph.D., Investigator of the Howard Hughes Medical Institute, Professor at the University of California at San Francisco and Professor at the University of California at Berkeley will be joining us with the latest info in kicking cancer's KRAS.
Time & Location
Apr 05, 2022, 6:00 PM – 7:30 PM EDT
Virtual/Live
About the Event
We're excited to welcome Kevan Shokat, Ph.D., University of California, San Francisco to the Kicking Cancer's KRAS Expert Series!
Kevan M. Shokat is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor in the Department of Chemistry at the University of California at Berkeley. He received his B.A. in Chemistry from Reed College in 1986, his Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz and carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow. Kevan’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases, and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011), and the American Academy of Arts and Sciences (2011). He has commercialized discoveries from his laboratory through co-founding several biotechnology companies including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines, Erasca and Kumquat Biosciences.
Learn more about Dr. Shokat here.
This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.
© 2024 KRAS Cancer Connect. All rights reserved. Nonprofit EIN 85-4372947